Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PPARγ agonists induce biased signaling in human adipocytes

ABSTRACT: Biased signaling and ligand bias, often referred to as functional selectivity or selective nuclear receptor modulation, have been reported for many nuclear receptor partial agonists over the past 20 years. However, whether differences in nuclear receptor signaling produced by partial and full agonists results from less intense partial agonist modulation, off-target effects, or biased signaling remains unclear. To determine whether biased signaling can occur through nuclear receptors we compare the transcriptional effects of two full agonists (which also favor different coactivator peptides) in human adipocytes. We also test the signaling effects of a partial agonist relative to full agonists. Furthermore, whether biased coactivator peptide recruitment translates to biased signaling in cells has not been determined. In a step towards this goal, we show that these same full agonists induce biased recruitment of 100-300 residue regions of coactivators containing all their nuclear receptor binding motifs. Together these data support the idea that nuclear receptor agonists can induce biased signaling through differences in coactivator recruitment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE266107 | GEO | 2025/10/26

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Mapping AT1R biased signaling using proximity-labeling and proteomics identifies diverse actions of biased agonists

Project description:Angiotensin II type 1 receptors (AT1Rs) are one of the most widely studied G protein-coupled receptors. To fully appreciate the diversity in cellular signaling profiles activated by AT1R transducer-biased ligands, we utilized peroxidase-catalyzed proximity labeling to capture proteins in close proximity to AT1Rs in response to six different ligands: Angiotensin II (full agonist), S1I8 (partial agonist), TRV055 and TRV056 (G protein-biased agonists), TRV026 and TRV027 (β-arrestin biased agonists) at 90s, 10min, and 60min after stimulation. We systematically analyzed the kinetics of AT1R trafficking and determined that distinct ligands lead AT1R to different cellular compartments for downstream signaling activation and receptor degradation/recycling. Distinct proximity labelling of proteins from a number of functional classes, including GTPases, adaptor proteins, and kinases were activated by different ligands suggesting unique signaling and physiological roles of the AT1R. Ligands within the same class, i.e. either G protein-biased or -arrestin-biased, shared high similarity in their labelling profiles. Comparison between ligand classes revealed distinct signaling activation such as greater labeling by G protein biased ligands on ESCRT-0 complex proteins that act as sorting machinery for ubiquitinated proteins. Our study provides a comprehensive analysis of AT1R receptor trafficking kinetics and signaling activation profiles induced by distinct classes of ligands.

2021-03-25 | PXD023814 | Pride

GRK-biased adrenergic agonists for the treatment of type II diabetes and obesity

Project description:Biased agonism of G protein-coupled receptors (GPCRs) holds great promise for the development of safer medications. Current efforts have explored the balance between heterotrimeric G proteins and the scaffold protein b-arrestin; however, other transducers like GPCR kinases (GRKs) represent important, but understudied mediators of agonist-induced signaling. In particular, GRK2 has been shown to play an essential role in b2 adrenergic receptor (b2AR)-mediated glucose uptake, but b2AR agonists are generally thought to make poor clinical candidates for glycemic management given their potential for Gs/cAMP-induced cardiac side effects and tendency for b-arrestin-dependent desensitization with long-term treatment. For these reasons, we sought to develop pathway-selective agonists of b2AR that prefer GRK coupling to heterotrimeric Gs and b-arrestin. Ligand-based virtual screening and chemical evolution of adrenergic agonists led to the identification of GRK-biased b2AR partial agonists. We demonstrate that these compounds perform well in preclinical models of hyperglycemia and obesity and demonstrate a lower potential for cardiac and muscular side effects compared to standard b2-receptor agonists and incretin mimetics respectively. Furthermore, our lead candidate showed favorable pharmacokinetics and was determined to be safe in a placebo-controlled clinical trial. GRK-biased b2AR partial agonists are thus promising candidates to offer a viable, orally available alternative to injection-based incretin mimetics used in the treatment of type II diabetes and obesity.

2025-05-05 | PXD058545 | Pride

Genome-wide maps of H3K4me1 in Mycobacterium tuberculosis H37Rv-infected macrophages

Project description:Host macrophage transcriptional responses to intracellular pathogens remain poorly characterized. We screened transcriptional enhancers engaged in response to M. tuberculosis (Mtb) infection by ChIPseq analysis of histone H3 lysine 4 monomethylation (H3K4me1). De novo monomethylation during infection was associated with genes implicated in host defense and apoptosis. These regions were enriched for binding sites for ETS transcription factor family members and response elements for nuclear receptors, including liver X receptors (LXRs) and peroxisomal proliferator activated receptors (PPARs), many of which were encompassed by transposable elements. LXRa expression was strongly induced by infection, whereas that of PPARs was unaffected. LXR DNA binding and NCoR corepressor recruitment increased proportionately in infected cells but coactivator association was unchanged, consistent with a lack of induction of endogenous agonists. However, treatment of infected cells with LXR agonist T0901317 strongly increased coactivator recruitment and induced a gene expression program characterized by enhanced innate immune signaling and lipid metabolism. Remarkably, T0901317 treatment selectively induced apoptosis in infected macrophages, and was accompanied by Mtb death, reducing mycobacterial burden 18-fold relative to vehicle 5d after infection. These studies define macrophage transcriptional responses to Mtb infection, and suggest that tissue-specific LXRa agonists may be efficacious in clinical management of tuberculosis.

2015-10-15 | E-MTAB-3192 | biostudies-arrayexpress

Ligand induced conformational changes in the B1-Adrenergic Receptor Revealed by Hydrogen-Deuterium Exchange Mass Spectrometry

Project description:Project employ Hydrogen Deuterium Exchange Mass Spectrometry (HDX-MS), to characterise the structural dynamics of turkey β1-adrenergic receptor (tβ1AR) in complex with nine ligands, including agonists, partial agonists and antagonists.We show that dynamic signatures across the GPCR structure can be grouped by compound modality. Surprisingly, we discovered repeated destabilisation of the intracellular loop 1 (ICL1) upon full agonist binding and stabilisation upon antagonist binding, suggesting that increased dynamics in this region are an essential component for G protein recruitment. Multiple sequence alignments and molecular dynamics simulations indicate that L72 in ICL1 plays an important structural role. Differential HDX-MS experiment of tβ1AR and tβ1AR L72A construct in complex with miniGs, in response to various ligands, suggests involvement of ICL1 in stabilising the GDP bound state by influencing the stability of HG helix of miniGs.

2024-08-30 | PXD051297 | Pride

Phosphorylation barcodes encoded by CXCR3 agonists direct biased chemokine signaling

Project description:Chemokine receptors (CKRs), a class of G protein-coupled receptors (GPCRs), interact with transducers like G proteins and β-arrestins. Many chemokines act as “biased agonists” that activate certain transducers over others. There has been limited success in pharmacologically targeting CKRs, with little evidence that differential receptor phosphorylation, or “phosphorylation barcodes,” direct biased responses. Here, we used mass spectrometry to demonstrate that CXCR3 chemokines generate different phosphorylation barcodes associated with differential activation of transducers. Chemokine stimulation resulted in distinct changes throughout the kinome in global phosphoproteomic studies. Mutation of CXCR3 phosphosites altered β-arrestin conformation and activation in molecular dynamics simulations. T-cells expressing phosphorylation-deficient CXCR3 mutants resulted in agonist- and receptor-specific chemotactic profiles not completely explained by engagement of G proteins and β-arrestins. Our results demonstrate that CXCR3 chemokines act as biased agonists through differential encoding of phosphorylation barcodes, and highlight the limitations of assessing GPCR physiology with proximal effector activity alone.

2023-05-24 | PXD034033 | JPOST Repository

Transcriptome Profiling of Ginsenoside Metabolites to Identify Estrogen Receptor Alpha Activity

Project description:20(S)-Protopanaxadiol (PPD) and 20(S)-Protopanaxatriol (PPT) are major metabolites of ginseng in humans and are considered to have estrogenic activity in cellular bioassays. In this study, we conducted in silico analyses to determine whether PPD and PPT interact with estrogen receptor alpha (ERα) and compared them with ERα agonists, partial agonists, and antagonists to identify their ERα activity.

2021-10-26 | GSE186470 | GEO

Transcription profiling of mouse treated with piperidine agonists for 24hr or 5 days for molecular characterization of novel peroxisome proliferator-activated receptor alpha agonists

Project description:The nuclear receptor PPARalpha is recognized as the primary target of the fibrate class of hypolipidemic drugs and mediates lipid lowering in part by activating a transcriptional cascade that induces genes involved in the catabolism of lipids. We report here the characterization of three novel PPARalpha agonists with therapeutic potential for treating dyslipidemia. These structurally related compounds display potent and selective binding to human PPARalpha and support robust recruitment of coactivator peptides in vitro. These compounds markedly potentiate chimeric transcription systems in cell-based assays and strikingly lower serum triglycerides in vivo. The transcription networks induced by these selective PPARalpha agonists were assessed by transcriptional profiling of mouse liver after acute and chronic treatment. The induction of several known PPARalpha target genes involved with fatty acid metabolism were observed, reflecting the expected pharmacology associated with PPARalpha activation. We also noted the downregulation of a number of genes related to immune cell function, the acute phase response, and glucose metabolism; suggesting that these compounds may have anti-inflammatory action in the mammalian liver. Taken together, these studies articulate the therapeutic promise of a selective PPARalpha agonist. Experiment Overall Design: Male C57Bl/6 mice (n=4 for all except 5 day treatment of 146-02 was n=2) were treated with the piperidine agonists for 24hr or 5 days at 1mg/kg/day, or water (vehicle) as control.

2008-12-02 | E-GEOD-12147 | biostudies-arrayexpress

Structure of the Homodimeric Androgen Receptor Ligand-Binding Domain

Project description:The androgen receptor (AR) plays a crucial role in normal physiology, development and metabolism as well as in the etiology and treatment of diverse pathologies such as androgen insensitivity syndromes (AIS), male infertility, and prostate cancer (PCa). Here, we show that dimerization of AR ligand-binding domain (LBD) is induced by receptor agonists but not by antagonists. The 2.15-Å crystal structure of homodimeric, agonist- and coactivator peptide bound AR-LBD unveils a 1,000-Å2 large dimerization surface, which harbors over 40 previously unexplained AIS- and PCa-associated point mutations. An AIS mutation in the self-association interface (P767A) disrupts dimer formation in vivo, and has a detrimental effect on the transactivating properties of full-length AR, despite retained hormone-binding capacity. The conservation of essential residues suggests that the newly unveiled dimerization mechanism might be shared by other nuclear receptors. Our work defines AR-LBD homodimerization as an essential step in the proper functioning of this important transcription factor.

2018-10-26 | PXD005575 | Pride

TurboID-based proxisome mapping of the human glucocorticoid receptor in A549 cells

Project description:Exogenous glucocorticoids are frequently used to treat inflammatory disorders and as adjuncts in solid cancers. However, their use is associated with severe side effects and therapy resistance. Novel glucocorticoid receptor (GR) ligands with a patient-validated reduced side effect profile have not yet reached the clinic. GR is a member of the nuclear receptor family of transcription factors and heavily relies on interactions with coregulator proteins for its transcriptional activity. To elucidate the role of the GR interactome in the altered transcriptional activity of GR following treatment with agonists, antagonists or lead selective GR agonists and modulators (SEGRAMs), we generated comprehensive interactome maps by high-confidence proximity proteomics in lung epithelial carcinoma cells. We found that the GR antagonist RU486 and the SEGRAM Dagrocorat both reduced GR interaction with CREB-binding protein (CBP)/p300 and the mediator complex compared to the full agonist Dexamethasone. Our data offer new insights into the role differential coregulator protein recruitment in shaping specific GR-mediated transcriptional responses.

2024-05-24 | PXD042014 | Pride

Mycobacterium tuberculosis H37Ra-infected macrophages response to T0901317

2016-01-31 | GSE64335 | GEO